Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2026 07:50 ET | Source: HCW Biologics Inc.

HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic

Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a transferable equity interest in licensee Initiation of...
June 04, 2025 08:20 ET | Source: HCW Biologics Inc.

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

MIRAMAR, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and...